Five High-Growth Small-Cap Medical Device Companies Reshaping 2024's Healthcare Investment Landscape

The small-cap medical device companies sector is experiencing remarkable momentum as chronic disease prevalence continues to surge globally. In 2024, the FDA approved 30 new devices, signaling the acceleration of innovation in medical technology. The global medical device industry is projected to expand from US$810.4 billion in 2024 to US$1.3 trillion by 2029, representing a compound annual growth rate of 9.8 percent—a trajectory that presents compelling opportunities for investors seeking exposure to this dynamic market. Among NASDAQ-listed small-cap medical device companies, five firms have emerged as particularly strong performers, each carving out distinctive niches in oncology, surgical technology, and therapeutic delivery.

Delcath Systems: Pioneering Targeted Cancer Treatment with 202% Annual Gains

Delcath Systems (NASDAQ: DCTH) has emerged as a breakout performer in the small-cap medical device sector, delivering a remarkable 202.86 percent year-over-year gain. With a market valuation of US$405.43 million and a share price of US$12.69, the company specializes in interventional oncology, focusing on innovative treatments for primary and metastatic liver cancers.

The company’s flagship offering—the Hepzato Kit, an FDA-approved combination of its Hepatic Delivery System (HDS) with the chemotherapeutic drug melphalan—represents a transformative approach to cancer treatment. By enabling high-dose chemotherapy directly to the liver while minimizing systemic exposure, Delcath has developed a product that addresses a significant clinical need. The HDS is also marketed in Europe as the Chemostat Hepatic Delivery System for Melphalan and carries Class III medical device regulation.

Throughout 2024, Delcath catalyzed multiple catalysts for growth. The company’s second quarter saw encouraging results from its FOCUS Study in metastatic uveal melanoma patients, accompanied by Q1 financials revealing revenues of US$3.1 million—a staggering 416 percent increase over the prior-year quarter. An independent study from Germany’s University Hospital of Leipzig validated the safety and efficacy of repeated chemosaturation treatments, propelling shares up an additional 37 percent in late August. By December, Delcath secured FDA clearance to initiate a Phase 2 trial evaluating Hepzato in combination with standard care for liver-dominant metastatic colorectal cancer, setting the stage for patient enrollment in the second half of 2025. The stock reached its yearly peak of US$12.79 on January 13 after the company announced preliminary full-year revenues of US$37.2 million.

Sensus Healthcare: Transforming Skin Cancer Treatment with 147% Returns

Sensus Healthcare (NASDAQ: SRTS) has positioned itself as a leading innovator in non-invasive skin cancer and keloid treatment, translating this focus into a 147.76 percent annual gain. The company’s market capitalization stands at US$108.01 million with a current share price of US$6.59.

The company’s proprietary superficial radiotherapy (SRT and IG-SRT) technology platform represents a patient-centric alternative to traditional interventions. In early 2024, Sensus announced landmark achievements: the inaugural sale of the SRT-100 Vision (IG-SRT) system in Asia and its first veterinary application in Israel, demonstrating technology versatility. Q1 2024 financials reinforced investor confidence, with revenues reaching US$10.7 million compared to US$3.4 million in the prior year. The company’s momentum accelerated in the latter half of 2024, with Q3 revenues of US$8.8 million (versus US$3.9 million year-over-year), sending shares to their yearly high of US$8.94 on November 20.

Pro-Dex: Surgical Innovation Fueling 118% Stock Appreciation

Pro-Dex (NASDAQ: PDEX) manufactures battery-powered and electrical surgical instruments deployed across orthopedic, spine, maxocranial facial, and dental markets. The company’s 118.55 percent annual gain reflects growing momentum in this specialized segment, with a current market cap of US$146.02 million and a share price of US$44.80.

Pro-Dex’s customer roster—including industry titans Smith & Nephew, Medtronic, and Arthrex—underscores the quality of its engineering and product performance. After announcing fiscal 2024 full-year results in early September, the stock surged 42 percent to US$31.34 by early October, driven by net sales growth of 41 percent in Q4 (ending June 30) to US$15 million and full-year growth of 17 percent to US$53.8 million. The company sustained this momentum into November 2024 with a 60 percent rally to US$49.55 per share following the release of fiscal 2025 Q1 results showing 25 percent sales growth to US$14.9 million.

AngioDynamics: Minimally Invasive Technology Delivering 92% Gains

AngioDynamics (NASDAQ: ANGO) represents the small-cap medical device companies frontier in minimally invasive devices, achieving a 92.18 percent annual return. With a market cap of US$477.29 million and a share price of US$11.80, the company addresses vascular access, surgical applications, peripheral vascular disease, and oncology.

The company’s innovation pipeline accelerated through 2024 with multiple regulatory victories. In mid-July, AngioDynamics announced its mechanical thrombectomy segment milestones: FDA 510(k) clearance and CE Marking for AlphaVac in pulmonary embolism treatment. This achievement, according to CEO Jim Clemmer, opened access to “multiple large, fast-growing markets” and contributed to a 68 percent sequential revenue increase for AlphaVac in Q4. In December, AngioDynamics secured FDA 510(k) clearance for its NanoKnife System for prostate tissue ablation, sparking a 31 percent rally to US$9.33. The stock reached its yearly peak of US$12.94 on January 8 following the release of fiscal 2025 Q2 results showing net sales of US$73 million, up 9.2 percent year-over-year.

KORU Medical Systems: Infusion Innovation Generating 85% Returns

KORU Medical Systems (NASDAQ: KRMD) develops and manufactures mechanical infusion products with an 85.84 percent annual gain and a market capitalization of US$186.56 million. The stock trades at US$4.07, reflecting the company’s growing presence in the therapeutic delivery space.

KORU’s primary products—the FREEDOM60, FreedomEdge Syringe Infusion Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets—build upon three decades of FDA-cleared technology heritage dating to 1994. The company’s strongest gains came in late 2024, with shares rising 67 percent from October-end to a yearly peak of US$4.40 on December 12. This momentum followed the October 31 release of data demonstrating nursing preference for the FreedomEdge System in subcutaneous oncology infusion compared to manual syringe administration. KORU’s Q3 2024 results revealed net revenues of US$8.2 million, representing 17 percent growth over the prior year.

The Broader Investment Thesis for Small-Cap Medical Device Companies

These five small-cap medical device companies collectively exemplify the sector’s structural strengths: aging populations driving chronic disease prevalence, accelerating FDA approval pace, and clinical validation of innovative treatment modalities. The 9.8 percent projected CAGR through 2029 suggests these are not isolated success stories but representatives of a broader industry transformation. For investors seeking exposure to healthcare innovation at potentially earlier stages of market development, the small-cap medical device companies space offers compelling diversification within the medical technology landscape.

Securities Disclosure: Analysis based on publicly available financial data through January 2025.